ImmunityBio Reports Record Q1 Revenue, Strong ANKTIVA Sales, and $381M Cash Position

summarizeSummary

ImmunityBio announced strong Q1 2026 financial results, including a 168% year-over-year increase in net product revenue and a significant boost in cash reserves, alongside positive clinical and regulatory advancements for ANKTIVA.

check_boxKey Events

• Record Q1 2026 Net Product Revenue

  Reported $44.2 million in net product revenue, a 168% increase year-over-year compared to Q1 2025 and a 15% sequential increase from Q4 2025, driven by strong ANKTIVA sales.

• Strengthened Cash Position

  Ended Q1 2026 with $380.9 million in cash, cash equivalents, and marketable securities, up from $242.8 million at year-end 2025, largely due to $223.9 million provided by financing activities.

• ANKTIVA Regulatory Expansion

  ANKTIVA is now approved or authorized across five regulatory jurisdictions (approximately 34 countries), including its first approval in Asia by Macau, and achieved commercial availability in MENA.

• Clinical Trial Progress

  The pivotal BCG-naïve CIS trial (QUILT-2.005) is fully enrolled, with an sBLA submission on track for 2026.

auto_awesomeAnalysis

ImmunityBio's Q1 2026 results demonstrate robust commercial momentum for ANKTIVA, with substantial revenue growth and unit sales increases. The company significantly strengthened its cash position through financing activities, providing a longer runway for operations and clinical development. Positive updates on the pivotal BCG-naïve NMIBC trial and expanded NCCN recommendations for ANKTIVA further de-risk future growth and market adoption. While the GAAP net loss increased due to non-cash fair value adjustments related to stock price appreciation and a one-time write-off, the underlying operational performance and cash generation are strong, indicating a positive trajectory for the company.